Howard S Hochster, MD

Professor of Medicine (Medical Oncology); Associate Director for Clinical Sciences, Yale Cancer Center; Clinical Program Leader, Gastrointestinal Cancers Program, Smilow Cancer Hospital; Clinical Research Program Leader, Gastrointestinal Cancers Program, Yale Cancer Center

Clinical Interests

  • Esophageal Neoplasms
  • Gastrointestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms
  • Colorectal Neoplasms

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center: Gastrointestinal Cancers Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine

  • Internal Medicine AB of Internal Medicine (1983)

  • Hematology (Internal Medicine) AB of Internal Medicine (1986)

Clinical Trials

Conditions Study Title
Anus, Rectum Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid A Phas 1a/b Dose Escalation Study of the Safety of OMP-131R10 IN Advanced Solid Tumors
Liver, Other Digestive Organ, Pancreas, Stomach Phase 1b Study of Atezolizumab + Bevacizumab and/or Other Treatments in Patients with Solid Tumors
Other Digestive Organ, Stomach Phase1b/2 Study of Margetuximab with Pembrolizumab in Patients with HER2+ GEJ or Gasctric Cancer
Colon, Rectum A Phase III Study of MK-3475 vs. Chemotherapy in MSI-H or dMMR Stage IV Colorectal Carcinoma
Liver Phase I/II Study of MEDI4736+Tremelimumab or Monotherapy in Subjects with Hepatocellular Carcinoma
Stomach Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment
Esophagus NCI 9824: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Pancreas Phase II Gemcitabine & Nab-paclitaxel +/- NPC-1C in metastatic or locally advanced pancreatic cancer
Other Digestive Organ, Stomach Phase 3 study of Ramucirumab in combination with Capecitabine & Cisplatin in pts with stomach cancer
Breast - Female, Breast - Male, Lung, Pancreas, Phase I Nivolumab in combination with nab-paclitaxel based therapy in Panc, NSCLC, and mBC
Pancreas Olaparib in gBRCA Mutated Pancreatic Cancer pts Not Progressed on 1st Line Platinum-Based Chemo
Esophagus, Other Digestive Organ Phase 1 study of DKN-01 plus Paclitaxel in pts with relapsed or refractory esophageal or GEJ cancer
Colon Pilot Study of Xolair in Reducing Oxaliplatin-induced HSR
Pancreas nab-paclitaxel plus gemcitabine in subjects with locally advanced pancreatic cancer
Pancreas S1313: Phase Ib/II Study of mFOLFIRINOX +PEGPH20 vs. mFOLFIRINOX in Met. Pancreatic Adenocarcinoma
Colon S0820: Preventing Adenomas of the Colon with Eflornithine and Sulindac
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Breast - Female, Lung, Ovary, Pancreas, Stomach, Phase I Phase 1/2 Study of Nivolumab or Nivolumab with Ipilimumab for Advanced or Metastatic Solid Tumors

Edit this profile